273
Participants
Start Date
November 23, 2021
Primary Completion Date
October 28, 2022
Study Completion Date
October 28, 2022
FASENRA(benralizumab)
This is a retrospective, observational study with secondary data collection utilizing medical chart review in hospitals or clinical centres that treated SEA + NP patients with benralizumab. Patient data including demographics, clinical characteristics, medication history, biologic treatment, and NP and asthma clinical outcomes will be abstracted from patient medical charts onto a pre-approved electronic case report form. No personal identifiable data will be collected. Data from all participating centres will be combined into a single anonymised dataset for analysis.
Research Site, New York
Research Site, The Bronx
Research Site, Glendale
Research Site, Cadiz
Research Site, Marseille
Research Site, Rochester
Research Site, A Coruña
Research Site, Philadelphia
Research Site, Milan
Research Site, Varese
Research Site, Norfolk
Research Site, Madrid
Research Site, Alcorcón
Research Site, Montpellier
Research Site, Salamanca
Research Site, Seville
Research Site, Modena
Research Site, Valencia
Research Site, Seville
Research Site, Florence
Research Site, Wiesbaden
Research Site, Lyon
Research Site, Centennial
Research Site, Napoli
Research Site, Denver
Research Site, Salerno
Research Site, Catanzaro
Research Site, Catania
Research Site, Ragusa
Research Site, Nantes
Research Site, Strasbourg
Research Site, Lübeck
Research Site, Orbassano
Research Site, Rome
Research Site, Chuo-ku, Niigata-Shi
Research Site, Hiroshima
Research Site, Moriguchi-Shi
Research Site, Nagaoka-Shi
Research Site, Shinagawa-ku
Research Site, Yonago-Shi
Research Site, Barcelona
Research Site, Madrid
Research Site, Monserrato
Research Site, Rome
Research Site, Barcelona
Lead Sponsor
AstraZeneca
INDUSTRY